OncoMatch/Clinical Trials/NCT06803693
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Is NCT06803693 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for diffuse large b-cell lymphoma.
Treatment: Polatuzumab vedotin · Rituximab · Cyclophosphamide · Doxorubicin · Prednisone · Zanubrutinib · Lenalidomide · Decitabine — The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 overexpression (CD20-positive)
CD20-positive DLBCL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
Hemoglobin ≥ 9.0 g/dL without packed RBC transfusion during 7 days before first treatment; ANC ≥ 1.0 x 10^9/L; PLT ≥ 75 x 10^9/L (unless due to underlying disease, as established for example, by extensive bone marrow involvement or due to hypersplenism secondary to involvement of the spleen by DLBCL per the investigator for which blood product transfusions are permitted)
Kidney function
Serum creatinine clearance ≥ 30 mL/min (using Cockcroft-Gault formula) (unless due to underlying lymphoma)
Liver function
Serum AST and ALT < 2.5 x ULN; Total bilirubin < 1.5 x ULN (unless due to underlying lymphoma)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac MUGA scan or ECHO
Adequate hematologic function...; Serum AST and ALT < 2.5 x ULN; Total bilirubin < 1.5 x ULN; Serum creatinine clearance ≥ 30 mL/min; LVEF ≥ 50% on cardiac MUGA scan or ECHO
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify